Reporting and Data Clause Samples
The Reporting and Data clause establishes the obligations of parties to provide, maintain, and share relevant information and data throughout the course of their agreement. Typically, this clause outlines the types of reports required, the frequency and format of data submissions, and any standards for data accuracy or confidentiality. Its core function is to ensure transparency and accountability between parties by setting clear expectations for information exchange, thereby reducing misunderstandings and supporting effective contract management.
Reporting and Data. Provider and Cigna will mutually agree, on the format, frequency and method of data files to be shared by Provider, to Cigna for reporting purposes in the Agreement or otherwise in writing (“Data Files”). This Service Level measures whether the Data Files provided by Provider match the agreed format, frequency and method. Provider will make available to Cigna the Data Files [***] as measured by the Provider and the Cigna. “[***]” shall mean that the Data File is available to Cigna by the [***]. “[***]” shall mean that the Data File matches the [***], including the data elements and record headers. This Service Level is calculated by dividing the [***].
2.11.1 Provider’s compensation for the reports, studies, information exchanges and data access delineated in this section and associated exhibits is fully incorporated in the rates and/or fee schedules and associated exhibits attached hereto. Provider shall receive no additional compensation for the reports, studies, information exchanges and data access. Provider agrees to collect data necessary to complete each report listed in the Performance Standards, Exhibit B to the Agreement.
Reporting and Data. Demonstrate the ability to maintain accurate, reliable, and timely data entry into the statewide early intervention database that accurately tracks each child served in Utah’s early intervention system. This will allow for timely and accurate reporting in alignment with state and federal reporting requirements.
Reporting and Data a. The Beneficiary will prepare and provide a progress report which captures activities, outputs and outcomes identified in the Work Plan as required by the County, and metrics from the 2021-2026 Douglas County Public Health Improvement plan if indicated, on a bi-annual basis, by July 30th for January to June activities, and by January 31st for July to December activities. The Beneficiary is required to report only activities, outputs and outcomes related to the funding received. The Beneficiary shall also prepare and provide a progress report ahead of contract renewal, if applicable, by October 31st each year.
b. The Happy Crew is a Beneficiary of ARPA Revenue Replacement funds. Treasury Guidance (SLFRF Final Rule FAQs) indicate that, “Treasury is not collecting subaward data for projects categorized under Expenditure Category Group 6, “Revenue Replacement.” Treasury has determined that there are no subawards under this eligible use category. The Beneficiary acknowledges that these reduced reporting standards are subject to change at the discretion of the US Department of Treasury, and agrees to provide such financial, performance, compliance reporting and/or records in such form as may be requested by the County. For this Contract, Douglas County staff shall:
A. Schedule, at a minimum, twice a year check-ins with the Beneficiary, or as needed to address any Beneficiary questions, or issues as they arise, for example, billing, reporting, etc.
B. Oversee contract management to include oversight and adherence to terms, reporting, amendments, and contract renewal.
Reporting and Data. (a) Upon request, Omnipharm shall promptly, but in no event later than thirty (30) days after such request provide Fidopharm with (i) a summary in reasonable detail of all data generated or obtained from each discrete Development activity performed under the Development Plan, such as any toxicology study, pharmacokinetics study or stability study, (ii) a summary of the Development progress against the projected Development progress set forth in the current Development Plan and (iii) a final report of the results of each Development activity, together with all material supporting data.
(b) Omnipharm shall provide Fidopharm copies of all substantive or material information with respect to the Development of Products, including clinical data compiled with respect to Products and all information and data filed with any governmental authority with respect to Products outside of the Territory, as soon as reasonably practicable after such information, data or results become available to or compiled by Omnipharm, including any drafts and final versions of any study reports (the “Development Data”). Subject to the terms and conditions of this Agreement, Fidopharm shall have the right to use the Development Data or any portion thereof for the purpose of obtaining Product Registrations and commercializing Products in the Territory.
Reporting and Data. Commencing on the Effective Date:
a. SCI shall provide weekly reports of process quality performance, including yield, defect pareto, root cause, and corrective actions. Process steps to be included in the reports are to be mutually agreed upon by McDATA and SCI. Level 2 and 3 Failures are included i▇ ▇▇▇▇e weekly reports.
b. SCI shall provide proof that delivered Product meets all requirements including the successful completion of all inspections and tests.
c. SCI shall report Failure Analysis queue levels on a weekly basis, including quantity in each troubleshoot location and aging of the items in each location.
Reporting and Data. Commencing on the Effective Date:
a. SUPPLIER shall provide weekly reports of process quality performance, including yield, defect pareto, root cause, and corrective actions. Process steps to be included in the reports are to be mutually agreed upon by Dot Hill and SUPPLIER. Level 2 and 3 Failures are included in these weekly reports.
b. SUPPLIER shall provide proof that delivered Product meets all requirements including the successful completion of all inspections and tests.
c. SUPPLIER shall report Failure Analysis queue levels on a weekly basis, including quantity in each troubleshoot location and aging of the items in each location.
Reporting and Data. (a) Upon request, ** shall promptly, but in no event later than thirty (30) days after such request provide Fidopharm with (i) a summary in reasonable detail of all data generated or obtained from each discrete Development activity performed under the Development Plan, such as any toxicology study, pharmacokinetics study or stability study, (ii) a summary of the Development progress against the projected Development progress set forth in the current Development Plan and (iii) a final report of the results of each Development activity, together with all material supporting data.
(b) shall provide Fidopharm copies of all substantive or material information with respect to the Development of Products, including clinical data compiled with respect to Products and all information and data filed with any governmental authority with respect to Products outside of the Territory, as soon as reasonably practicable after such information, data or results become available to or compiled by **, including any drafts and final versions of any study reports (the “Development Data”). Subject to the terms and conditions of this Agreement, Fidopharm shall have the right to use the Development Data or any portion thereof for the purpose of obtaining Product Registrations and commercializing Products in the Territory.
Reporting and Data